Study: Artisanal CBD-Rich Extracts Show Long-Term Efficacy in Children with Epilepsy

1 min readPublished On: September 22nd, 2022By
TEL AVIV–(NORML) According to findings published in Pediatric Neurology, long-term treatment with plant-derived CBD extracts is effective for children with refractory epilepsy.

Israeli researchers evaluated the efficacy and safety of artisanal CBD-rich extracts in a group of young people with types of epilepsy that are resistant to therapy. 51 percent of patients who received extracts for at least a year saw a significant decrease in the frequency of their seizures. Patients only had minor negative effects from CBD therapy.

“Artisanal cannabidiol-enriched cannabis may be an effective and safe long-term treatment for refractory epilepsy,” the authors wrote in their conclusion.

In 2018, the US Food and Drug Administration approved the sale of Epidiolex, a prescription drug used to treat Lennox-Gastaut syndrome and Dravet syndrome, two uncommon forms of severe epilepsy. Epidiolex contains a standardized formulation of cannabidiol produced from plants. The US Drug Enforcement Administration promptly downgraded Epidiolex to Schedule V of the US Controlled Substances Act, the category with the fewest restrictions permitted by federal law.

Full text of the study, “The long-term effectiveness and safety of cannabidiol-enriched oil in children with drug-resistant epilepsy,” appears in Pediatric NeurologyAdditional information on cannabis and epilepsy is available from NORML.

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News

  • Financial Result, CBD Skin Care Market, Cannabis Testing Market

Global Cannabis Testing Market Analysis Report 2023-2030

February 4th, 2023|

DUBLIN - Global Cannabis Testing Market to Reach $2.8 Billion by 2030 In the changed post COVID-19 business landscape, the global market for Cannabis Testing estimated at US$1.1 Billion in the year 2022, is projected to reach ...